Skip Nav Destination
Issues
1 November 2018
-
Cover Image
Cover Image
The cover shows a section of an adrenal biopsy from a patient with metastatic melanoma who responded to anti-PD1 therapy. Fluorescent immunohistochemical staining shows high colocalization of PD-L1 (red) and PD1 (yellow) with S100 (green) and DAPI (blue). For details, see the article by Johnson and colleagues on page 5250 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
Reviews
Clinical Trial Brief Report
Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM Study
Clément Bailly; Thomas Carlier; Bastien Jamet; Thomas Eugene; Cyrille Touzeau; Michel Attal; Cyrille Hulin; Thierry Facon; Xavier Leleu; Aurore Perrot; Laurent Garderet; Margaret Macro; Denis Caillot; Philippe Moreau; Françoise Kraeber-Bodéré; Caroline Bodet-Milin
Clinical Trials: Targeted Therapy
Author Choice
Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer
Shilpa Gupta; Luke T. Nordquist; Mark T. Fleming; William R. Berry; Jingsong Zhang; Sharon L. Ervin; Joel R. Eisner; Edwina S. Baskin-Bey; Neal D. Shore
Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma
Yihebali Chi; Zhiwei Fang; Xiaonan Hong; Yang Yao; Ping Sun; Guowen Wang; Feng Du; Yongkun Sun; Qiong Wu; Guofan Qu; Shusen Wang; Jianmin Song; Jianchun Yu; Yongkui Lu; Xia Zhu; Xiaohui Niu; Zhiyong He; Jinwan Wang; Hao Yu; Jianqiang Cai
Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma
Regina Alemany; David S. Moura; Andres Redondo; Javier Martinez-Trufero; Silvia Calabuig; Carlos Saus; Antonia Obrador-Hevia; Rafael Ramos; Victor H. Villar; Claudia Valverde; Maria Angeles Vaz; Javier Medina; Irene Felipe-Abrio; Nadia Hindi; Miguel Taron; Javier Martin-Broto
Precision Medicine and Imaging
Author Choice
Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti–PD-1 Therapies in Metastatic Melanoma
Douglas B. Johnson; Jennifer Bordeaux; Ju Young Kim; Christine Vaupel; David L. Rimm; Thai H. Ho; Richard W. Joseph; Adil I. Daud; Robert M. Conry; Elizabeth M. Gaughan; Leonel F. Hernandez-Aya; Anastasios Dimou; Pauline Funchain; James Smithy; John S. Witte; Svetlana B. McKee; Jennifer Ko; John M. Wrangle; Bashar Dabbas; Shabnam Tangri; Jelveh Lameh; Jeffrey Hall; Joseph Markowitz; Justin M. Balko; Naveen Dakappagari
Evolutionary Expression of HER2 Conferred by Chromosome Aneuploidy on Circulating Gastric Cancer Cells Contributes to Developing Targeted and Chemotherapeutic Resistance
Yilin Li; Xiaotian Zhang; Dan Liu; Jifang Gong; Daisy Dandan Wang; Shan Li; Zhi Peng; Yanyan Li; Xiaojuan Wang; Peter Ping Lin; Min Li; Lin Shen
Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept “3G” Trial
Wei Peng Yong; Sun Young Rha; Iain Bee-Huat Tan; Su-Pin Choo; Nicholas L. Syn; Vivien Koh; Shi-Hui Tan; Bernadette Reyna Asuncion; Raghav Sundar; Jimmy Bok-Yan So; Asim Shabbir; Chee-Seng Tan; Hyo-Song Kim; Minkyu Jung; Hyun Cheol Chung; Matthew C.H. Ng; David Wai-Meng Tai; Ming-Hui Lee; Jeanie Wu; Khay Guan Yeoh; Patrick Tan; on behalf of the Singapore Gastric Cancer Consortium (SGCC)
TERT Promoter Mutation Detection in Cell-Free Tumor-Derived DNA in Patients with IDH Wild-Type Glioblastomas: A Pilot Prospective Study
Tareq A. Juratli; Sebastian Stasik; Amir Zolal; Caroline Schuster; Sven Richter; Dirk Daubner; Mazen A. Juratli; Rachel Thowe; Silke Hennig; Meriem Makina; Matthias Meinhardt; Tim Lautenschlaeger; Gabriele Schackert; Dietmar Krex; Christian Thiede
Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
Maki Tanioka; Cheng Fan; Joel S. Parker; Katherine A. Hoadley; Zhiyuan Hu; Yan Li; Terry M. Hyslop; Brandelyn N. Pitcher; Matthew G. Soloway; Patricia A. Spears; Lynn N. Henry; Sara Tolaney; Chau T. Dang; Ian E. Krop; Lyndsay N. Harris; Donald A. Berry; Elaine R. Mardis; Eric P. Winer; Clifford A. Hudis; Lisa A. Carey; Charles M. Perou
Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Post Hoc Analysis of the PR.7 Trial
Paul Toren; Azik Hoffman; Keyue Ding; France-Hélène Joncas; Véronique Turcotte; Patrick Caron; Frédéric Pouliot; Yves Fradet; Éric Lévesque; Chantal Guillemette; Laurence Klotz
Translational Cancer Mechanisms and Therapy
Author Choice
Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias
Michael W. Schmitt; Justin R. Pritchard; Scott M. Leighow; Bella I. Aminov; Lan Beppu; Daniel S. Kim; J. Graeme Hodgson; Victor M. Rivera; Lawrence A. Loeb; Jerald P. Radich
Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations
Curtis H. Kugel, III; Stephen M. Douglass; Marie R. Webster; Amanpreet Kaur; Qin Liu; Xiangfan Yin; Sarah A. Weiss; Farbod Darvishian; Rami N. Al-Rohil; Abibatou Ndoye; Reeti Behera; Gretchen M. Alicea; Brett L. Ecker; Mitchell Fane; Michael J. Allegrezza; Nikolaos Svoronos; Vinit Kumar; Daniel Y. Wang; Rajasekharan Somasundaram; Siwen Hu-Lieskovan; Alpaslan Ozgun; Meenhard Herlyn; Jose R. Conejo-Garcia; Dmitry Gabrilovich; Erica L. Stone; Theodore S. Nowicki; Jeffrey Sosman; Rajat Rai; Matteo S. Carlino; Georgina V. Long; Richard Marais; Antoni Ribas; Zeynep Eroglu; Michael A. Davies; Bastian Schilling; Dirk Schadendorf; Wei Xu; Ravi K. Amaravadi; Alexander M. Menzies; Jennifer L. McQuade; Douglas B. Johnson; Iman Osman; Ashani T. Weeraratna
Author Choice
Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor–Engineered T Cells for Ovarian Cancer
Tatsuo Matsuda; Matthias Leisegang; Jae-Hyun Park; Lili Ren; Taigo Kato; Yuji Ikeda; Makiko Harada; Kazuma Kiyotani; Ernst Lengyel; Gini F. Fleming; Yusuke Nakamura
Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration
Ayman Oweida; Mohammad K. Hararah; Andy Phan; David Binder; Shilpa Bhatia; Shelby Lennon; Sanjana Bukkapatnam; Benjamin Van Court; Nomin Uyanga; Laurel Darragh; Hyun Min Kim; David Raben; Aik Choon Tan; Lynn Heasley; Eric Clambey; Raphael Nemenoff; Sana D. Karam
Metabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma
Chiaki T. Ishida; Yiru Zhang; Elena Bianchetti; Chang Shu; Trang T.T. Nguyen; Giulio Kleiner; Maria J. Sanchez-Quintero; Catarina M. Quinzii; Mike-Andrew Westhoff; Georg Karpel-Massler; Varun V. Prabhu; Joshua E. Allen; Markus D. Siegelin
The Splicing Factor PTBP1 Promotes Expression of Oncogenic Splice Variants and Predicts Poor Prognosis in Patients with Non–muscle-Invasive Bladder Cancer
Pamela Bielli; Valentina Panzeri; Rossano Lattanzio; Simona Mutascio; Marco Pieraccioli; Elisabetta Volpe; Vincenzo Pagliarulo; Mauro Piantelli; Antonella Giannantoni; Savino M. Di Stasi; Claudio Sette
The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications
Diego Iglesias-Gato; Elin Thysell; Stefka Tyanova; Sead Crnalic; Alberto Santos; Thiago S. Lima; Tamar Geiger; Jürgen Cox; Anders Widmark; Anders Bergh; Matthias Mann; Amilcar Flores-Morales; Pernilla Wikström
IFNL4-ΔG Allele Is Associated with an Interferon Signature in Tumors and Survival of African-American Men with Prostate Cancer
Wei Tang; Tiffany A. Wallace; Ming Yi; Cristina Magi-Galluzzi; Tiffany H. Dorsey; Olusegun O. Onabajo; Adeola Obajemu; Symone V. Jordan; Christopher A. Loffredo; Robert M. Stephens; Robert H. Silverman; George R. Stark; Eric A. Klein; Ludmila Prokunina-Olsson; Stefan Ambs
Letters to the Editor
Corrections
Retraction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds